Share-based Payment Arrangement, Expense in USD of BeOne Medicines Ltd. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BeOne Medicines Ltd. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2014 to Q3 2025.
  • BeOne Medicines Ltd. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $141M, a 22.8% increase year-over-year.
  • BeOne Medicines Ltd. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $495M, a 15.9% increase year-over-year.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2024 was $442M, a 20.2% increase from 2023.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $368M, a 21.3% increase from 2022.
  • BeOne Medicines Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $303M, a 25.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

BeOne Medicines Ltd. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $495M $141M +$26.2M +22.8% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 $468M $151M +$19.9M +15.2% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 $449M $95.5M +$6.74M +7.59% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 $442M $108M +$15M +16.2% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025
Q3 2024 $427M $115M +$18.5M +19.2% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 $408M $131M +$27.4M +26.5% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 $381M $88.7M +$13.3M +17.7% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 $368M $92.8M +$14.6M +18.7% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025
Q3 2023 $353M $96.1M +$17.9M +23% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $335M $103M +$22M +27.1% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 $313M $75.4M +$9.83M +15% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 $303M $78.1M +$15.1M +24% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025
Q3 2022 $288M $78.2M +$11.1M +16.5% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 $277M $81.3M +$16.5M +25.5% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023
Q1 2022 $260M $65.6M +$19.7M +43% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023
Q4 2021 $241M $63M +$13.6M +27.4% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024
Q3 2021 $227M $67.1M +$16.8M +33.4% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $210M $64.8M +$19.3M +42.5% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 $191M $45.8M +$7.58M +19.8% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 $183M $49.5M +$11.1M +29% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023
Q3 2020 $172M $50.3M +$13.5M +36.6% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 $159M $45.5M +$12.9M +39.5% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $146M $38.3M +$11.9M +44.9% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $134M $38.3M +$12.4M +47.7% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022
Q3 2019 $122M $36.8M +$11.7M +46.5% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 $110M $32.6M +$14M +74.9% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 $96.1M $26.4M +$9M +51.7% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 $87.1M $26M +$9.5M +57.7% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021
Q3 2018 $77.6M $25.1M +$11.8M +88.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 $65.8M $18.6M +$11.6M +163% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 $54.3M $17.4M +$11.4M +190% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $42.9M $16.5M +$12.5M +317% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020
Q3 2017 $30.3M $13.3M +$10.5M +380% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018
Q2 2017 $19.8M $7.08M +$5.8M +451% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 $14M $5.99M +$3.38M +129% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018
Q4 2016 $10.6M $3.95M +$1.78M +82.1% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019
Q3 2016 $8.85M $2.78M -$2.04M -42.3% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 $10.9M $1.29M +$375K +41.2% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 $10.5M $2.61M +$300K +13% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017
Q4 2015 $10.2M $2.17M 01 Oct 2015 31 Dec 2015 10-K 28 Feb 2018
Q3 2015 $4.82M 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 $910K 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 $2.31M 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016

BeOne Medicines Ltd. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $442M +$74.2M +20.2% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025
2023 $368M +$64.4M +21.3% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025
2022 $303M +$62.5M +25.9% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025
2021 $241M +$57.2M +31.2% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024
2020 $183M +$49.3M +36.8% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023
2019 $134M +$47M +54% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022
2018 $87.1M +$44.3M +103% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021
2017 $42.9M +$32.2M +303% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020
2016 $10.6M +$414K +4.05% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019
2015 $10.2M +$3.57M +53.9% 01 Jan 2015 31 Dec 2015 10-K 28 Feb 2018
2014 $6.64M 01 Jan 2014 31 Dec 2014 10-K 22 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.